

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 39252

Title: Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model

Reviewer's code: 03478772

Reviewer's country: Taiwan

Science editor: Fang-Fang Ji

Date sent for review: 2018-06-21

Date reviewed: 2018-06-21

Review time: 13 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

My pleasure to review the article by Garg et al. The manuscript is well-written. I have the following suggestions for further improvement of the paper: #1. The term, LTB, should be introduced as a heat-labile enterotoxin of E. coli at the first appearance in the

main text. #2. The statement, 'We reported previously that the recombinant Survivin vaccine is efficacious in preventing the growth of 4T-1 based murine model of breast cancer (13).' was tagged with a wrong citation. Reference #13 is an article written by none of the current authors. #3. In view of the above, all other references should be checked for appropriateness and correctness. #4. Page 11. Second paragraph, Line 3. Please add premenopausal before breast cancers. In the human model, LHRH agonists are used in premenopausal women only. #5. Figure 2. The legend. Interferon-gamma, not interferon-y. #6. Table 1. In the first row of Table, Right column, please add 'lung' before nodules. #7. Because the authors have previously published several papers regarding the basic science innovative research using two recombinant proteins, Survivin and luteinizing hormone-releasing hormone fusion protein [LHRH(6leu)-LTB] for immunotherapy of breast cancer, I would challenge the authors in this paper to draw a colorful diagram showing the mechanistic steps from reconstruction of the recombinant proteins to act as a vaccine targeting what pathway in breast cancer. This figure can be put into the Discussion section to enrich the entire article.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

https:// www.wjgnet.com

[] Plagiarism

[Y] No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 39252

Title: Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model

Reviewer's code: 00209021

Reviewer's country: Turkey

Science editor: Fang-Fang Ji

Date sent for review: 2018-07-06

Date reviewed: 2018-07-09

Review time: 3 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear editor, The manuscript is well written and deserves publication. Below is some minor issues: -Abstract section: In methods the authors should give details of the study groups. -Abstract section: In results the authors should give their important findings



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

with p values. -Abstract section: Comments in results should be transferred to conclusion. -Core tip: The authors should provide their important findings -Discussion section: The authors should mention about the limitations of the study.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 39252

Title: Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model

Reviewer's code: 00183194

Reviewer's country: China

Science editor: Fang-Fang Ji

Date sent for review: 2018-07-06

Date reviewed: 2018-07-13

Review time: 7 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

1.Please explain the distinguish of LHRH(6leu)-LTB, LHRH(6leu)-LTB proteins, LHRH and LHRH fusion protein. It really confused us. 2.From fig.1, we found that the volume of tumor was significantly suppressed by survivin at a does of 20 ug. While,



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

increase in vaccine dose to 50 μ g did not lead to any significant inhibition in tumor volume. Please explain which is dose-inhibition related effects and the potential mechanism. 3.what's more, there are only two groups of survivin in fig.1. Thus, we could not get the conclusion that there is a dose-inhibition related effects. We think there is at least 5 group of different does of survivin. 4.From the figure 2, we confused that which take the main role in suppressing tumor volume. Please explain the relationship among svrvivin, anti-survivin antibodies and IFN- levels. 5.Please provided the figure of gross tumor and metastatic lung tumor.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No